2nd ESCMID Conference on The Impact of Vaccines on Public Health

22 - 24 March 2013, Prague, Czech Republic

Conference material

All conference materials (slides, webcasts) can be found in the ESCMID Online Lecture Library

Conference Objectives

As part of its multifaceted approach to infections, ESCMID strives to promote vaccination and worries that the current lack of correct information among both lay public and healthcare providers might seriously undermine the efficacy of current and future vaccine campaigns. This conference will bring together world-leading experts to debate the many-sided correlations between vaccines, medicine and society at the dawn of the third millennium.

Conference Venue

Ambassador Congress Hall
Vaclavske namesti 5–7
11124 Prague, Czech Republic

Target Audience

Specialists or physicians in training in infectious diseases, clinical microbiology, hygiene, public health, vaccinology and other disciplines dealing with all aspects of vaccination.

Registration Procedure

Please download the registration form (see link on the right) and return it to the conference secretariat.

Registration Fee

Members of ESCMID and Affiliated Societies

  • Before and on 8 January 2013: EUR 500
  • After 8 January 2013: EUR 600

All others

  • Before and on 8 January 2013: EUR 700
  • After 8 January 2013: EUR 800

The registration fee includes the scientific sessions, printed conference material, lunches and coffee breaks, but not travel and accommodation costs.

Scientific Secretariat

Giuseppe Cornaglia
Dept. of Pathology and Diagnostics
University of Verona
Phone +39 045 802 71 96
Fax +39 045 802 71 01

Conference Secretariat

Marco Moschin
Via Lorenzo Marcello 32
30126 Lido di Venezia
Phone +39 041 52 62 530
Fax +39 041 52 71 129

Scientific Programme

Friday, 22 March 2013
The role of WHO-Europe/ECDC
Chairs: Giuseppe Cornaglia & Jaroslav Blahos
09.00The role of WHO-Europe. Dina Pfeifer
09.30The role of ECDC. Piotr Kramarz
10.00Coffee break
Paediatric and adolescent vaccination
Chairs: Dina Pfeifer & Sarka Nemeckova
10.30Multivalent paediatric vaccines. Susanna Esposito
11.00The possible evolution of paediatric influenza vaccination in Europe.
Kari Johansen
11.30Measles elimination and the interruption of indigenous transmission.
Dina Pfeifer
12.00Chickenpox vaccination: a laboured take off. Paloma Carrillo-Santisteve
Vaccines for adults
Chairs: Vincenzo Bronte & Roman Chlibek
14.00Lifelong vaccination as a key disease - prevention strategy. Paolo Bonanni
14.30Influenza immunisation in elderly. Patricia Blank
15.00Pertussis boostering in adults. Maarten J. Postma
15.30Coffee break
Vaccines and women: more than a gender issue
Chairs: Pierluigi Lopalco & Eva Hamsikova
16.00The potential role of GBS vaccination: overall value and the hurdles of prenatal programmes. Paul Heath
16.30Eliminating rubella and preventing congenital rubella syndrome in Europe. Mark Muscat
17.00Implementing HPV vaccination: where do we stand now? Mario Poljak
17.30Next-generation HPV vaccines: challenges and perspective. Elmar Joura
Saturday, 23 March 2013
Chairs: Mario Poljak & Petr Pazdiora
08.00Hepatitis B vaccination in Western European countries. Pierre Van Damme
08.30Hepatitis A vaccination: can we do better? Dina Pfeifer
09.00Hepatitis E vaccines: phase II and phase III trials.
Wai Kuo Shih & Ning-Shao Xia
09.30Hepatitis C vaccines: myth or reality? Sergio Abrignani
10.00Coffee break
Vaccines for encephalitis and viral haemorrhagic fevers
Chairs: Raul E. Isturiz & Lenka Strakova
10.30Tetravalent Dengue vaccine – from research to phase III. Ragnar Norrby
11.00Japanese Encephalitis vaccines. Katrin Dubischar-Kastner
11.30Recombinant DNA-derived vaccines for VHF. Connie S. Schmaljohn
12.00Tick borne encephalitis. Franz X. Heinz
Novel vaccine targets
Chairs: Karen Kotloff & Frantisek Stejskal
13.30CMV vaccine: phase II trial results. Christoph Steininger
14.00New and candidate vaccines for gastrointestinal infections. Karen Kotloff
14.30Norovirus vaccine: first results. Timo Vesikari
15.00Vaccines to constrain antimicrobial resistance. Ron Dagan
15.30Malaria vaccine research and development: Status and first results from the ongoing phase 3 trial of the RTS,S candidate. Joe Cohen
16.00Coffee break
Pneumococcal vaccines and their implementation strategy
Chairs: Ron Dagan & Roman Prymula
16.30Pneumococcal infection in adults: burden of disease. Gernot Rohde
17.00Pneumococcal vaccination in the EU: current status and perspectives. Bernard Fritzell
17.30Role of vaccines in preventing pneumococcal diseases. Stefano Aliberti   
18.00Pneumococcal vaccination: do we need a new implementation strategy? Pavla Krizova

Sunday, 24 March 2013
Novel vaccines for old diseases
Chairs: Rino Rappuoli & Jana Prattingerova
08.00Flu vaccination facing flu virus mutability. Albert Osterhaus
08.30Innovative strategies for meningococcal vaccines. Mariagrazia Pizza
09.00New vaccines against tuberculosis. Giovanni Delogu
09.30A vaccine for Staphylococcus aureus? Richard A. Proctor
10.00Coffee break
Towards the future: technological challenges and vaccine policies
Chairs: Giovanni Rezza & Pavla Krizova
10.30From genomics to structural vaccinology. Rino Rappuoli
11.00The rationale for conjugate vaccines. Dennis Kasper
11.30Actual immunisation coverage throughout Europe: are existing data sufficient? Pierluigi Lopalco
12.00Emerging economies from consumers to new donor countries.
Suresh Jadhav
12.30Contrasting the anti-vaccine movements. Robb Butler